InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,856.88
(
0.72%
)
US TECH 100
19,890.00
(
0.79%
)
Dow Jones
43,023.44
(
0.37%
)
Brent Oil
77.60
(
0.17%
)
Bitcoin
65,713.82
(
4.56%
)

Replies to post #358238 on Anavex Life Sciences Corp (AVXL)

Replies to #358238 on Anavex Life Sciences Corp (AVXL)
icon url

RedShoulder

04/24/22 11:23 PM

#358242 RE: Bourbon_on_my_cornflakes #358238

[quote. We need follow up to PDD and PD far more than another rare disease


Well said Bourbon, that is where he can easily 'show us the money'. Yet here we sit with the stock at $10. SMH

High dose improved all patients, and importantly without any adverse effects.

The data from the Ph-2 trial is a hands down winner, a foregone conclusion for FDA approval.

People need to pepper Dr. M with questions at the ASM about the tortoise rate of follow up trials.



Especially PDD/PD which is still not in a Phase -3 since the highly successful results were PRed in June of last year.

Where is the PDD/PD paper that was to be published, if you have the trial results in hand, how long does it take?
icon url

crescentmotor

04/24/22 11:47 PM

#358252 RE: Bourbon_on_my_cornflakes #358238

We need followup to PDD and PD far more than another rare disease.



I would characterize the lack of AVXL follow-up to the amazing trial results reported almost one year ago as inexcusable. PD is a huge market and there should be a sense of urgency. I could care less about a Phase I for a rare disease indication. Just think about how valuable it would have been to have another successful trial in the PD area in the back pocket if the AD Phase 2b/III implodes.